Quotables
"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187608 | Treatment of Fibrosis related disorders The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are p... | 05/29/2012 |
| 8178107 | Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and m... | 05/15/2012 |
| 8178109 | Compositions and methods of use for MGD-CSF in disease treatment Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure... | 05/15/2012 |
| 8178108 | Methods for expression and purification of recombinant human growth hormone The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encod... | 05/15/2012 |
| 8168588 | Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby... | 05/01/2012 |
| 8168199 | Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor caus... | 05/01/2012 |
| 8163695 | Formulations of human growth hormone comprising a non-naturally encoded amino acid Formulations of modified human growth hormone polypeptides are provided. ... | 04/24/2012 |
| 8158582 | Methods for treatment of insulin-like growth factor-1 deficiency The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. Th... | 04/17/2012 |
| 8147844 | ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using ligand Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakar... | 04/03/2012 |
| 8124099 | Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble... | 02/28/2012 |
| 8114839 | Protease resistant modified erythropoietin polypeptides Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and u... | 02/14/2012 |
| 8101188 | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arte... | 01/24/2012 |
| 8084421 | Method of reducing blood glucose levels in type 2 diabetes patients by administering granulocyte-colony stimulating factor A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors. ... | 12/27/2011 |
| 8075902 | Diagnosis and treatment of cancer related to human dormancy New devices and methods for diagnosis and compositions and methods for treatment of cancers use combinations of antimicrobial agents and agents that can reverse dormancy and hibernation pathways. We unexpectedly found that surprisingly low doses of anti-hibernation ... | 12/13/2011 |
| 8057802 | Treatment methods for fibrosis related disorders The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are p... | 11/15/2011 |
| 8052976 | Growth factor homolog ZVEGF3 Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residu... | 11/08/2011 |
| 8029799 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases. ... | 10/04/2011 |
| 8017129 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases. ... | 09/13/2011 |
| 7998929 | Solution preparations stabilized over long time A G-CSF solution formulation which is substantially free from proteins as a stabilizer but which contains at least one amino acid or a salt thereof as a stabilizer. ... | 08/16/2011 |
| 7994124 | Methods of use of G-CSF cysteine muteins The present invention relates to therapeutic methods for a protecting an animal from a disease or condition that can be treated by granulocyte colony-stimulating factor (G-CSF) wherein a composition comprising a cysteine variant of G-CSF is provided. Also disclosed ... | 08/09/2011 |
| 7976847 | Controlled release CGRP delivery composition for cardiovascular and renal indications The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods... | 07/12/2011 |
| 7973007 | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammatio... | 07/05/2011 |
| 7956034 | FSH glycosylation variant D3N FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described. ... | 06/07/2011 |
| 7951381 | Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with th... | 05/31/2011 |
| 7951380 | Methods of stimulating bone growth using ZVEGF4 polypeptides Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residu... | 05/31/2011 |
| 7951382 | Methods for treatment of type 2 diabetes The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the in... | 05/31/2011 |
| 7947285 | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis The invention relates generally to methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmac... | 05/24/2011 |
| 7943143 | Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vac... | 05/17/2011 |
| 7935351 | Use of CPG oligodeoxynucleotides to induce angiogenesis This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The discl... | 05/03/2011 |
| 7919103 | Compound and method for regulating plasminogen activation and cell migration The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention rela... | 04/05/2011 |
| 7867500 | Cofactor that modulates steroid receptor activities The invention provides a new glucocorticoid receptor coactivator named STAMP (Steroid receptor coactivator-1 and Transcription intermediary factor-2 Associated Modulatory Protein) that can modulate transcription of glucocorticoid-, progesterone-, mineralocorticoid- ... | 01/11/2011 |
| 7862824 | Enhancement of GLP-2 activity of suppressing appetite The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination com... | 01/04/2011 |
| 7862826 | Trophic factor combinations for nervous system treatment The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective a... | 01/04/2011 |
| 7862825 | Method of controlling tight blood glucose by somatostatin receptor antagonists The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemi... | 01/04/2011 |
| 7850976 | Insulin resistance improving agents The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improv... | 12/14/2010 |
| 7846453 | Methods of stimulating ErbB4 receptor phosphorylation The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention... | 12/07/2010 |
| 7838005 | Treatment of insulin resistance by administering an acid-sensing ion channel 3 inhibitor Disclosed are a method of for treating insulin resistance and a method identifying a compound for treating insulin resistance. ... | 11/23/2010 |
| 7820179 | Pegylated PTH as PTH receptor modulators and uses thereof Pharmaceutical compositions and methods are provided for the treatment and prevention of bone loss diseases including osteoporosis in a mammal. ... | 10/26/2010 |
| 7820178 | VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof. ... | 10/26/2010 |
| 7815912 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of —a substance having follicle stimulating hormone activity (FSH substance) in... | 10/19/2010 |
